Medication Regimen Adjustment for Elderly Patients with Diabetes

Rationale for Regimen Simplification

The American Diabetes Association recommends that elderly patients with long-standing or complicated disease should have less ambitious glycemic targets, with an A1C of 7.5-8.0% being acceptable, as the risk of hypoglycemic events can be detrimental in the elderly and may lead to increased morbidity and mortality, including falls, fractures, and cardiovascular events 1, 2
For an 88-year-old patient, an A1C of 8.0% is actually reasonable and may not require aggressive intensification, and the current four-drug regimen represents excessive polypharmacy for minimal additional benefit at this age 2

The American Diabetes Association and European Association for the Study of Diabetes recommend discontinuing Januvia (sitagliptin) as the incremental benefit is minimal and adds unnecessary complexity and cost, especially when metformin, an SGLT2 inhibitor, and basal insulin already provide comprehensive glycemic coverage 1
Elderly patients are at increased risk for volume depletion, orthostatic hypotension, and falls when using SGLT2 inhibitors like Jardiance (empagliflozin), and it should be used cautiously in patients with poor mobility or urinary incontinence 3

Metformin should be continued if renal function is adequate (CrCl >30 mL/min), as it provides foundational glucose control with minimal hypoglycemia risk, and monitor renal function regularly to avoid lactic acidosis risk 1, 3
The basal insulin dose should be the primary tool for achieving the target A1C of 7.5-8.0%, and starting insulin doses should be reduced to 0.1-0.15 units/kg/day, given mainly as basal insulin, to avoid overbasalization 1, 2

Measure A1C every 3 months to assess whether the simplified regimen maintains adequate control, and home blood glucose monitoring should be individualized based on the pharmacologic regimen 5
Monitor for hypoglycemia awareness, falls, and cognitive changes, as these are critical safety outcomes in elderly patients that outweigh modest A1C improvements 2

Avoid aggressive glucose lowering in pursuit of A1C <7.0% in this age group, as the risks of hypoglycemia, polypharmacy, and treatment burden outweigh any theoretical microvascular benefits 1, 2
Avoid sliding-scale insulin regimens, as they increase hypoglycemia risk, and do not use long-acting sulfonylureas due to prolonged hypoglycemia risk 3